93 related articles for article (PubMed ID: 18323787)
1. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
Arafeh R; Flores K; Keren-Paz A; Maik-Rachline G; Gutkind N; Rosenberg S; Seger R; Samuels Y
Sci Rep; 2017 Nov; 7(1):16345. PubMed ID: 29180761
[TBL] [Abstract][Full Text] [Related]
3. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.
Murphy BM; Terrell EM; Chirasani VR; Weiss TJ; Lew RE; Holderbaum AM; Dhakal A; Posada V; Fort M; Bodnar MS; Carey LM; Chen M; Burd CJ; Coppola V; Morrison DK; Campbell SL; Burd CE
Nat Commun; 2022 Jun; 13(1):3153. PubMed ID: 35672316
[TBL] [Abstract][Full Text] [Related]
4. Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma.
Kim YJ; Bond GJ; Tsang T; Posimo JM; Busino L; Brady DC
Metallomics; 2019 Aug; 11(8):1430-1440. PubMed ID: 31317143
[TBL] [Abstract][Full Text] [Related]
5. Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization.
Verlande A; Krafčíková M; Potěšil D; Trantírek L; Zdráhal Z; Elkalaf M; Trnka J; Souček K; Rauch N; Rauch J; Kolch W; Uldrijan S
EMBO Rep; 2018 Feb; 19(2):320-336. PubMed ID: 29263201
[TBL] [Abstract][Full Text] [Related]
6. MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function.
Pascucci FA; Ladelfa MF; Toledo MF; Escalada M; Suberbordes M; Monte M
Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118918. PubMed ID: 33279609
[TBL] [Abstract][Full Text] [Related]
7. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Palmer AA; Zhang XD; Thompson JF; Bron LP; Hersey P
J Clin Pathol; 2005 Nov; 58(11):1163-9. PubMed ID: 16254105
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of RKIP and p-ERK in gastric cancer.
Fujimori Y; Inokuchi M; Takagi Y; Kato K; Kojima K; Sugihara K
J Exp Clin Cancer Res; 2012 Mar; 31(1):30. PubMed ID: 22463874
[TBL] [Abstract][Full Text] [Related]
9. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Wang W; Edington HD; Jukic DM; Rao UN; Land SR; Kirkwood JM
Cancer Immunol Immunother; 2008 Sep; 57(9):1315-21. PubMed ID: 18386001
[TBL] [Abstract][Full Text] [Related]
10. PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.
Yang G; Liu S; Maghsoudloo M; Shasaltaneh MD; Kaboli PJ; Zhang C; Deng Y; Heidari H; Entezari M; Fu S; Wen Q; Imani S
Sci Rep; 2021 Mar; 11(1):6056. PubMed ID: 33723350
[TBL] [Abstract][Full Text] [Related]
11. Pathway Alterations in Stage II/III Primary Melanoma.
Kostrzewa CE; Luo L; Arora A; Seshan VE; Ernstoff MS; Edmiston SN; Conway K; Gorlov I; Busam K; Orlow I; Hernando-Monge E; Thomas NE; Berwick M; Begg CB; Shen R;
JCO Precis Oncol; 2023 Mar; 7():e2200439. PubMed ID: 36926987
[TBL] [Abstract][Full Text] [Related]
12. BRAF: A Two-Faced Janus.
Pisapia P; Pepe F; Iaccarino A; Sgariglia R; Nacchio M; Russo G; Gragnano G; Malapelle U; Troncone G
Cells; 2020 Nov; 9(12):. PubMed ID: 33260892
[TBL] [Abstract][Full Text] [Related]
13. ERK mediates interferon gamma-induced melanoma cell death.
Champhekar A; Heymans R; Saco J; Turon Font G; Gonzalez C; Gao A; Pham J; Lee J; Maryoung R; Medina E; Campbell KM; Karin D; Austin D; Damioseaux R; Ribas A
Mol Cancer; 2023 Oct; 22(1):165. PubMed ID: 37803324
[TBL] [Abstract][Full Text] [Related]
14. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.
Hernandez B; Adissu HA; Wei BR; Michael HT; Merlino G; Simpson RM
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385676
[TBL] [Abstract][Full Text] [Related]
15. P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma.
Banik I; Ghosh A; Beebe E; Burja B; Frank Bertoncelj M; Dooley CM; Markkanen E; Dummer R; Busch-Nentwich EM; Levesque MP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765834
[TBL] [Abstract][Full Text] [Related]
16. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
Garman B; Anastopoulos IN; Krepler C; Brafford P; Sproesser K; Jiang Y; Wubbenhorst B; Amaravadi R; Bennett J; Beqiri M; Elder D; Flaherty KT; Frederick DT; Gangadhar TC; Guarino M; Hoon D; Karakousis G; Liu Q; Mitra N; Petrelli NJ; Schuchter L; Shannan B; Shields CL; Wargo J; Wenz B; Wilson MA; Xiao M; Xu W; Xu X; Yin X; Zhang NR; Davies MA; Herlyn M; Nathanson KL
Cell Rep; 2017 Nov; 21(7):1936-1952. PubMed ID: 29141224
[TBL] [Abstract][Full Text] [Related]
17. Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.
Ma W; Wu Z; Maghsoudloo M; Ijaz I; Dehghan Shasaltaneh M; Zhang Y; Weng Q; Fu J; Imani S; Wen QL
PLoS One; 2023; 18(7):e0285806. PubMed ID: 37432950
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?
Massi D; Mandalà M
Melanoma Manag; 2015 Feb; 2(1):5-8. PubMed ID: 30190824
[No Abstract] [Full Text] [Related]
19. The E3/E4 ubiquitin ligase UFD-2 suppresses normal and oncogenic signaling mediated by a Raf ortholog in
Townley R; Deniaud A; Stacy KS; Rodriguez Torres CS; Cheraghi F; Wicker NB; de la Cova CC
Sci Signal; 2023 Aug; 16(800):eabq4355. PubMed ID: 37643243
[TBL] [Abstract][Full Text] [Related]
20. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
Sigaud R; Albert TK; Hess C; Hielscher T; Winkler N; Kocher D; Walter C; Münter D; Selt F; Usta D; Ecker J; Brentrup A; Hasselblatt M; Thomas C; Varghese J; Capper D; Thomale UW; Hernáiz Driever P; Simon M; Horn S; Herz NA; Koch A; Sahm F; Hamelmann S; Faria-Andrade A; Jabado N; Schuhmann MU; Schouten-van Meeteren AYN; Hoving E; Brummer T; van Tilburg CM; Pfister SM; Witt O; Jones DTW; Kerl K; Milde T
Nat Commun; 2023 Jul; 14(1):4533. PubMed ID: 37500667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
